Key facts
- This page summarizes Samir R. Patel's Form 4 filing for Akari Therapeutics Plc (AKTX).
- 6 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 17 Jul 2026, 06:03.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Options Exercise
Options Exercise
No transaction description listed
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Options Exercise
Options Exercise
Additional SEC filing notes
Footnote F1
Each American Depositary Share ("ADS") represents 80,000 ordinary shares with a par value of $0.000000005 per ordinary share.
Footnote F2
The pre-funded warrants remain exercisable until fully exercised.
Footnote F3
The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026.
Footnote F4
The combined purchase price per one pre-funded warrant and accompanying Series G Warrant was $16.16.
Footnote F5
On December 16, 2025, the Reporting Person and the Issuer entered into a note cancellation and exchange agreement, pursuant to which, in exchange for the entire outstanding principal amount and all accrued interest on the Issuer's unsecured promissory note held by the Reporting Person, the Issuer issued to the Reporting Person (i) pre-funded warrants (the "Note Exchange Unregistered Pre-Funded Warrants") to purchase up to 5,799 ADSs, at a purchase price of $16.16 per Note Exchange Unregistered Pre-Funded Warrant, and (ii) warrants to purchase up to 5,799 ADSs.